Pilot Study of CoolTXT for Non-Invasive Fat Reduction
This study has been completed.
Information provided by (Responsible Party):
First received: January 4, 2012
Last updated: October 14, 2014
Last verified: January 2012
This study is being performed to reduce unwanted fat, in various body areas, using a new applicator and control unit for Zeltiq.
Body Fat Disorder
Device: The Zeltiq System
||Intervention Model: Single Group Assignment
Masking: Open Label
||Pilot Study of CoolTXT for Non-Invasive Fat Reduction
Primary Outcome Measures:
- Efficacy Assessment through Ultrasound Measurements [ Time Frame: 16 weeks post final treatment ] [ Designated as safety issue: No ]
The primary endpoint will be analyzed by percent reduction in fat layer thickness, as measured by ultrasound.
• Safety endpoint: incidence of device- or procedure-related adverse events. Acceptance criteria - zero incidences of UADEs.
Secondary Outcome Measures:
- Outcome Measured by Photo Review and Subject Satisfaction Questionnaire [ Time Frame: 16 weeks post final treatment ] [ Designated as safety issue: No ]
- Comparison of pre- and 16-week post final treatment photographs of the treatment area(s).
- Subject satisfaction as assessed by questionnaires administered at 16 weeks post final treatment.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 2014 (Final data collection date for primary outcome measure)
No Intervention: Fat Reduction
Device: The Zeltiq System
Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
The purpose of this study is to evaluate the safety and feasibility of a new product under development for non-invasive fat reduction. The new product delivers controlled cooling via a conformable surface applicator, rather than the existing vacuum applicator. A range of treatment parameters will be investigated. At the investigator's discretion, each treatment area may receive up to 3 treatments, spaced 2 - 8 weeks apart. The subjects will return for follow-up at 2 months and 4 months after final treatment. Therefore, the entire study period may last up to 8 months.
|Ages Eligible for Study:
||18 Years to 65 Years (Adult)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male or female subjects > 18 years of age and < 65 years of age.
- Subject has clearly visible fat on intended treatment area(s), which in the investigator's opinion, may benefit from the treatment(s). Treatment areas include: abdomen, saddlebag (outer aspect of upper thighs), upper arms and inner thighs.
- Subject has not had weight change exceeding 10 pounds in the preceding month.
- Subject with body mass index (BMI) between 25 and 35. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches.
- Subject agrees to maintain his/her weight (i.e., within 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study.
- Subject has read and signed a written informed consent form.
- Subject has had a surgical procedure(s) in the area of intended treatment.
- Subject has had an invasive fat reduction procedure (e.g., liposuction, abdominoplasty, mesotherapy) in the area of intended treatment.
- Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 6 months.
- Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
- Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.
- Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.
- Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
- Subject is taking or has taken diet pills or supplements within the past month.
- Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
- Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system
- Subject is pregnant or intending to become pregnant in the next 8months.
- Subject is lactating or has been lactating in the past 6 months.
- Subject is unable or unwilling to comply with the study requirements.
- Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
- Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01517646
|Arbutus Laser Centre
|Vancouver, British Columbia, Canada, V6J IZ6 |
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 4, 2012
||October 14, 2014
||United States: Institutional Review Board
Keywords provided by Zeltiq Aesthetics:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 21, 2016
Lipid Metabolism Disorders